"Navigating the Modern News Zoo so you don't have to."
Sunday, September 7, 2025
Osimertinib plus chemotherapy improves progression-free survival in EGFR-mutated non-small cell lung cancer
A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy.
đ Full Story
2 Popular Stocks Retail Investors Are Buying & What Super Investors Are Doing Now
- Mike Johnson Makes Shocking Claim About Trump Involvement In Epstein Saga - Mark Tanos
- Will the Fed Lower Rates in September? Experts Say Weak Jobs Report âCementsâ a Cut
- Elon Musk's Ambitious Plan: To Send One Million Humans to Mars within the Next Decade - Michael A. Medeiros
- Anti-vaccine RFK Jr. creates vaccine panel of anti-vaccine groupâs dreams - Beth Mole
- The Evolution and Impact of Internet Jokes: A Closer Look at Prank.Chat - Bertha Stephens
- The Full Moons of 2024: A Comprehensive Guide to Their Names and Dates - Arya Chandran
20 Years of Renting vs. Buying a Home in Canada (2005 to 2024)
- God-Given Rights: The Profoundly Ignorant Tim Kaine - Paul Kengor
- The Right Way to Go After Venezuelan Drug Traffickers - The Editors
- 8 Worst Foods for Your Prostate Health - Merve Ceylan
- Amazon Expands Jobs and Services in Rural America
- iOS 18 Elevates the iPhone with Unmatched Personalization and Intelligence - Michael A. Medeiros
- Sydney Sweeney's Sexy New Ad Causes More Strange Controversy - Joshua Tyler
